Brief: Cumberland Pharmaceuticals Says FDA Sent Co Goal Extension Letter To Allow Additional Time To Review Application For Methotrexate Product Line
23/08/2019 22:13
Aug 23 (Reuters) - Cumberland Pharmaceuticals Inc CPIX.O :
* CUMBERLAND PHARMACEUTICALS - ON AUG 22, FDA SENT CO GOAL
EXTENSION LETTER TO ALLOW ADDITIONAL TIME TO REVIEW APPLICATION
FOR METHOTREXATE PRODUCT LINE
* CUMBERLAND PHARMACEUTICALS INC - FDA SET A NEW PDUFA
ACTION
DATE FOR METHOTREXATE PRODUCT LINE OF EARLY DECEMBER 2019
Source: (https://bit.ly/325eJ1f)
Further company coverage: CPIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cumberland Pharmaceuticals
See all newsBrief: Cumberland Pharmaceuticals Announces Assist-Ssc Trial Top-Line Results
Cumberland Pharmaceuticals Q2 loss widens after Apotex transaction
Brief: Cumberland Pharmaceuticals Announces Special Dividend Of $1.50 Per Share
Cumberland Pharmaceuticals Q1 revenue up 5%; to sell FDA‑approved brands to Apotex for $100 mln
NASDAQ RESUMED AT 09:38 AM